Bristol-myers Squibb Compnay

Xiang Shao

Alan J Korman

Mark J Selby

Mohan Srinivasan

Nils Lonberg

Arvind Rajpal

Guodong Chen

Maria N Jure-Kunkel

Ginger Chao Rakestraw

Aaron Paul Yamniuk

Richard Y Huang

Kent B Thudium

Han Chang

Karla Ann Henning

Mark F Maurer

Xi-Tao Wang

Indrani Chakraborty

Brenda L Stevens

Michelle Minhua Han

Jochem Gokemeijer

Shrikant Deshpande

Bryan C Barnhart

Alexander T Kozhich

Christine Bee

Ming Lei

Thomas D Kempe

Vangipuram S Rangan

Michael Quigley

Sandra V Hatcher

Susan Chien-Szu Wong

Liang Schweizer

Natalie Bezman

Hadia Lemar

Christina Maria Milburn

Patrick Guirnalda

Amy D Jhatakia

Zhehong Cai

Marie-Michelle Navarro Garcia

Praveen Aanur

Zheng Yang

Christine Huang

Yan Feng

Maria Rodriguez

The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)

Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)

Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against OX-40 and uses thereof

Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies

Antibodies against OX40 and uses thereof

Growing community of inventors

Milpitas, CA, United States of America

Xiang Shao